# Frazier Life Sciences Management, 13F Q2 2026

Frazier Life Sciences Management, L.P. reported $4.6 billion in 13F securities across 41 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Mirum Pharmaceuticals Inc at $899 million, 19.6% of the reported value. Since Q1 2026 it opened 6 new positions and exited 3.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $4,592,076,814
- Positions: 41
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1892134
- Form 13F file number: 028-22504
- CRD number: 317522
- Business address: 1001 Page Mill Road Building 4, Suite 200b, Palo Alto, CA 94304
- SEC filing: [0001892134-26-000003](https://www.sec.gov/Archives/edgar/data/1892134/000189213426000003/0001892134-26-000003-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/frazier-life-sciences-management-lp-317522)

## Top 25 holdings by value

The largest of 41 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 7,679,684 | $899.1 million | No change |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 18,088,902 | $613 million | +1,145,128 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 24,975,188 | $457.5 million | +300,000 |
| [MBX Biosciences Inc](https://specstream.ai/data/institutional-holders/mbx-biosciences-inc-55287l101) | COM | 6,652,013 | $367.2 million | No change |
| [Arcutis Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/arcutis-biotherapeutics-inc-03969k108) | COM | 9,874,511 | $258.9 million | No change |
| [Trevi Therapeutics Inc](https://specstream.ai/data/institutional-holders/trevi-therapeutics-inc-89532m101) | COM | 9,939,447 | $185.4 million | -100 |
| [Krystal Biotech Inc](https://specstream.ai/data/institutional-holders/krystal-biotech-inc-501147102) | COM | 481,307 | $178.9 million | No change |
| [Maze Therapeutics Inc](https://specstream.ai/data/institutional-holders/maze-therapeutics-inc-578784100) | COM | 5,032,915 | $150.2 million | +465,641 |
| [Phathom Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/phathom-pharmaceuticals-inc-71722w107) | COM | 12,466,489 | $135.3 million | No change |
| [Palvella Therapeutics Inc Ne](https://specstream.ai/data/institutional-holders/palvella-therapeutics-inc-ne-697947109) | COM | 882,400 | $134.8 million | No change |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 1,548,139 | $115.3 million | -1,900,000 |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 1,354,852 | $99.1 million | No change |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 1,159,879 | $98.8 million | No change |
| [Dyne Therapeutics Inc](https://specstream.ai/data/institutional-holders/dyne-therapeutics-inc-26818m108) | COM | 3,153,082 | $70 million | No change |
| Ascendis Pharma A/S | SPONSORED ADR | 225,155 | $60.1 million | +91,822 |
| [Savara Inc](https://specstream.ai/data/institutional-holders/savara-inc-805111101) | COM | 9,720,852 | $59.9 million | No change |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 1,920,805 | $52.6 million | New |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 7,100,000 | $50.4 million | +2,000,000 |
| [Achieve Life Science Inc](https://specstream.ai/data/institutional-holders/achieve-life-science-inc-004468500) | COM | 7,614,836 | $49.7 million | New |
| [Vor Biopharma Inc](https://specstream.ai/data/institutional-holders/vor-biopharma-inc-929033207) | COM NEW | 2,543,939 | $46.8 million | No change |
| [Allogene Therapeutics Inc](https://specstream.ai/data/institutional-holders/allogene-therapeutics-inc-019770106) | COM | 22,446,668 | $46.7 million | +18,650,000 |
| [Tarsus Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/tarsus-pharmaceuticals-inc-87650l103) | COM | 728,644 | $45.9 million | No change |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 4,009,240 | $40.1 million | No change |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 700,647 | $36.7 million | No change |
| [Acadia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/acadia-pharmaceuticals-inc-004225108) | COM | 1,438,198 | $36.4 million | No change |

## New positions in Q2 2026

6 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 1,920,805 | $52.6 million |
| [Achieve Life Science Inc](https://specstream.ai/data/institutional-holders/achieve-life-science-inc-004468500) | COM | 7,614,836 | $49.7 million |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 1,809,854 | $26.2 million |
| [Shattuck Labs Inc](https://specstream.ai/data/institutional-holders/shattuck-labs-inc-82024l103) | COM | 3,750,000 | $26 million |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 1,100,000 | $24.2 million |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 1,015,693 | $19 million |

## Positions exited in Q2 2026

3 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Kalvista Pharmaceuticals Inc | COM | 4,961,108 | $99.9 million |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 675,686 | $65.7 million |
| [Agios Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/agios-pharmaceuticals-inc-00847x104) | COM | 1,256,080 | $42.5 million |

## Also on SpecStream

- [Frazier Life Sciences Management, L.P. Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1892134/000189213426000003/0001892134-26-000003-index.htm)
- [Frazier Life Sciences Management, L.P. investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/frazier-life-sciences-management-lp-317522)
- [Largest 13F filers in California](https://specstream.ai/data/institutional-holdings/state/california)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Palo Alto, California

- [Engineering firms in Palo Alto, California](https://specstream.ai/data/businesses/engineering-firms/palo-alto-california-united-states)
- [Banks and credit unions in Palo Alto, California](https://specstream.ai/data/businesses/banks-and-credit-unions/palo-alto-california-united-states)
- [Preschools in Palo Alto, California](https://specstream.ai/data/businesses/preschools/palo-alto-california-united-states)
- [Interior design firms in Palo Alto, California](https://specstream.ai/data/businesses/interior-design-firms/palo-alto-california-united-states)
- [Doctors' offices in Palo Alto, California](https://specstream.ai/data/businesses/doctors-offices/palo-alto-california-united-states)
- [Accounting firms in Palo Alto, California](https://specstream.ai/data/businesses/accounting-firms/palo-alto-california-united-states)
